<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bartter and Gitelman syndromes in children: Clinical manifestations, diagnosis, and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bartter and Gitelman syndromes in children: Clinical manifestations, diagnosis, and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bartter and Gitelman syndromes in children: Clinical manifestations, diagnosis, and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin Konrad, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1953899649"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inherited hypokalemic salt-losing tubulopathies, which include Bartter- and Gitelman-like syndromes, are disorders in which salt (ie, sodium) reabsorption is impaired, resulting in excretion of salt in excess of what is required for homeostasis  (<a class="graphic graphic_table graphicRef131049" href="/d/graphic/131049.html" rel="external">table 1</a>). These disorders result from pathogenic variants in genes that affect proteins regulating sodium and chloride reabsorption. These proteins are located in the thick ascending limb (TAL), distal convoluted tubule (DCT), and connecting tubule/collecting duct. Clinical manifestations vary depending on the affected protein.</p><p>The clinical manifestations, diagnosis, and treatment of Bartter syndrome (BS) and Gitelman syndrome (GS) in children are presented here.</p><p>The clinical manifestations, diagnosis, and treatment of BS and GS in adults, as well as an overview that describes the classification of inherited salt-losing tubulopathies and the pathophysiology of inherited hypokalemic salt-losing tubulopathies, are discussed separately. (See  <a class="medical medical_review" href="/d/html/131196.html" rel="external">"Bartter and Gitelman syndromes in adults: Diagnosis and management"</a> and  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations"</a>.)</p><p class="headingAnchor" id="H3287303098"><span class="h1">TERMINOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tubular reabsorption</strong> is the process by which large amounts of ultrafiltrate produced by the kidney during the excretion of waste products are recovered by the kidney tubules. Water and many solutes are reabsorbed back into the bloodstream by the action of transporters, channels, and paracellular pathways along the kidney tubules, thereby maintaining homeostasis. Tubular reabsorption is energy intensive, which is why the kidneys match the heart as having the highest resting metabolic expenditure (approximately 440 kcal/kg per day).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tubulopathy</strong> is defined as dysfunction of the kidney tubules, typically causing defects in reabsorption; these can be either inherited or acquired. The list of inherited tubulopathies is long, given the array of transported solutes [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salt-losing (or salt-wasting) tubulopathies</strong> are defined as disorders in which salt (ie, sodium) reabsorption is impaired, resulting in excretion of salt in excess of what is required for homeostasis. These tubulopathies are among the most commonly encountered in clinical practice  (<a class="graphic graphic_table graphicRef131049" href="/d/graphic/131049.html" rel="external">table 1</a>) [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bartter syndrome (BS)</strong> is defined as inherited disorders caused by molecular defects that effect sodium chloride (NaCl) reabsorption in the cortical and medullary thick ascending limbs (TALs) of the loop of Henle  (<a class="graphic graphic_figure graphicRef131048" href="/d/graphic/131048.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gitelman syndrome (GS)</strong> is defined as an inherited disorder resulting in defective NaCl reabsorption in the distal convoluted tubule (DCT)  (<a class="graphic graphic_figure graphicRef131045" href="/d/graphic/131045.html" rel="external">figure 2</a>).</p><p></p><p class="headingAnchor" id="H3335245822"><span class="h1">GENETIC CLASSIFICATION</span><span class="headingEndMark"> — </span>Before the genetic defects were identified, an eponymous nomenclature was used to describe <strong>hypokalemic</strong> salt-losing tubulopathies as either BS or GS. With the discovery of the underlying genes responsible for these disorders, it became clear that mutations in the same gene can produce significant phenotypic diversity among different individuals with overlap among the two named syndromes. As a result, hypokalemic inherited tubulopathies are better described phenotypically as Bartter-like syndrome and Gitelman-like syndrome. The terms BS (types 1 through 5) and GS are used in association with specific genotypes and will be used in this topic. The terms Bartter-like and Gitelman-like syndromes are used to describe the expressed phenotype regardless of the underlying gene defect  (<a class="graphic graphic_table graphicRef131049" href="/d/graphic/131049.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1451812186"><span class="h2">Bartter syndrome</span><span class="headingEndMark"> — </span>BS is manifested by typical gene-specific patterns resulting from dysfunctional proteins causing impaired sodium chloride (NaCl) reabsorption in the cortical and medullary thick ascending limb (TAL) of the loop of Henle. BS is divided into several types based on the causative gene defect  (<a class="graphic graphic_figure graphicRef131048" href="/d/graphic/131048.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef132709" href="/d/graphic/132709.html" rel="external">table 2</a>) [<a href="#rid3">3</a>]. A more detailed description of the underlying pathophysiology of these defects is presented separately. (See  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations", section on 'Pathophysiology'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>BS type 1</strong> – BS type 1 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601678&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyptBCcoyKKSC8ipWyVlLxbe&amp;TOPIC_ID=131435" target="_blank">MIM #601678</a>) is caused by defects in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600839&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoxvKHEeILathayIHXf3Piz&amp;TOPIC_ID=131435" target="_blank"><i>SLC12A1</i></a>, which encodes the Na-K-2Cl cotransporter (NKCC2). Defective NKCC2 function mimics the effects of loop diuretics, which block this pathway directly [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BS type 2</strong> – BS type 2 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F241200&amp;token=tEpDslnpc0F0kICl%2Fz7sFZDxK7ki9TNJyVXNO7kDVoNWLXBiHK%2F1z4%2Fmvqo6YewL&amp;TOPIC_ID=131435" target="_blank">MIM #241200</a>) is caused by defects in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600359&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrHjld6cINu6QsBJdXiwAGn&amp;TOPIC_ID=131435" target="_blank"><i>KCNJ1</i></a>, which encodes the apical potassium channel KCNJ1 (also referred to as ROMK) [<a href="#rid5">5</a>]. Defective KCNJ1 function inhibits NaCl reabsorption along the TAL as potassium must recycle from cells back into the luminal fluid to maintain the action of NKCC2. This channel also participates in aldosterone-driven potassium secretion along distal segments, resulting in less severe hypokalemia for patients with BS2 compared with those with other types of BS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – The following genes encode proteins that are components of chloride channel exit pathways from the TAL. Chloride reabsorbed via NKCC2 exits the cell on the basolateral side predominantly through the chloride channel ClC-Kb. Barttin is a necessary subunit for both chloride channels ClC-Kb and ClC-Ka. Pathologic variants of these genes impede chloride flow out of the cell and into the blood stream.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>BS type 3</strong> – BS type 3 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607364&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrPuafO5pHdmmJ%2BLakn38Y8&amp;TOPIC_ID=131435" target="_blank">MIM #607364</a>) is caused by defects in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602023&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqTD%2Fcsip0f9OWr9NgZTSD3&amp;TOPIC_ID=131435" target="_blank"><i>CLCNKB</i></a>, which encodes ClC-Kb [<a href="#rid6">6</a>]. ClC-Kb also mediates basolateral chloride transport in the distal convoluted tubule (DCT), and this might explain the overlapping phenotype between patients with BS type 3 and those with Gitelman-like syndrome. (See <a class="local">'Gitelman syndrome'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>BS type 4a</strong> – BS type 4a (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602522&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoI41%2FSInG8yTE5SNhr75Gp&amp;TOPIC_ID=131435" target="_blank">MIM #602522</a>) is caused by defects in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606412&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoTdMGTrXMkw66hSZ%2FM2Vq9&amp;TOPIC_ID=131435" target="_blank"><i>BSND</i></a>, which encodes barttin. Defective barttin function results in a typically very severe antenatal form of BS and is associated with sensorineural deafness [<a href="#rid7">7,8</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>BS type 4b</strong> – BS type 4b (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613090&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6g4cSo5q7NbXh%2FXkuxUoe9&amp;TOPIC_ID=131435" target="_blank">MIM #613090</a>) is caused by a combination of pathologic variants of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602024&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrEv0qgPPa19%2FubnQKwtt7H&amp;TOPIC_ID=131435" target="_blank"><i>CLCNKA</i></a> (encoding ClC-Ka) and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602023&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqTD%2Fcsip0f9OWr9NgZTSD3&amp;TOPIC_ID=131435" target="_blank"><i>CLCNKB</i></a> [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BS type 5</strong> – BS type 5 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300971&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6H0AL2YFzdQGCw%2Fs3UjpRCL&amp;TOPIC_ID=131435" target="_blank">MIM #300971</a>) is caused by pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300470&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GY6BRfKcr1Pxyz%2BTzetl0q&amp;TOPIC_ID=131435" target="_blank"><i>MAGED2</i></a> gene that encodes MAGE-D2 (melanoma-associated antigen). These defects disrupt trafficking of NKCC2 and NCC to the apical membrane of TAL and DCT cells, although the underlying mechanism remains unclear [<a href="#rid10">10,11</a>]. Affected patients present with severe antenatal BS, which resolves after birth, at latest within two years.</p><p></p><p class="headingAnchor" id="H1182941746"><span class="h2">Gitelman syndrome</span><span class="headingEndMark"> — </span>GS (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F263800&amp;token=tEpDslnpc0F0kICl%2Fz7sFVotXPSmMDaW2EHangYam63aetmBPLxWChzvgSI6tBid&amp;TOPIC_ID=131435" target="_blank">MIM #263800</a>) is caused by dysfunctional proteins that affect NaCl reabsorption in the DCT. Classic GS is due to biallelic pathogenic variants of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600968&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqhcOVSWaUgDzdK8hjFTA8C&amp;TOPIC_ID=131435" target="_blank"><i>SLC12A3</i></a> gene that encodes the NaCl cotransporter NCC, expressed in the apical membrane of the DCT [<a href="#rid12">12</a>]  (<a class="graphic graphic_figure graphicRef131045" href="/d/graphic/131045.html" rel="external">figure 2</a>).</p><p>Other gene variants that have been identified in individuals with Bartter- or Gitelman-like syndrome include <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602208&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoMs2JCgoFI1e27V8d18rgu&amp;TOPIC_ID=131435" target="_blank"><i>KCNJ10</i></a> (also known as Kir4.1, encodes a glial potassium channel, and causes <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F612780&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7SwUlg4PDioH6QPkfdcgGQ&amp;TOPIC_ID=131435" target="_blank">EAST/SESAME syndrome</a>), <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602023&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqTD%2Fcsip0f9OWr9NgZTSD3&amp;TOPIC_ID=131435" target="_blank"><i>CLCNKB</i></a> (encodes ClC-Kb, which is found in both DCT and TAL), <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608268&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaE6vyGmo4HKjN07rs03xDbH&amp;TOPIC_ID=131435" target="_blank"><i>RRAGD</i></a> (encodes the small GTPase RagD), and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F590045&amp;token=tEpDslnpc0F0kICl%2Fz7sFdjD%2BQo2qciDf1%2FZrD6VV4vxRT5ilZkVx9DBGbTiXmxp&amp;TOPIC_ID=131435" target="_blank"><i>MT</i>-<i>TI</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F590070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdjD%2BQo2qciDf1%2FZrD6VV4vrrzcGOrezlPjZ8wsREmBo&amp;TOPIC_ID=131435" target="_blank"><i>MT</i>-<i>TF</i></a> (mitochondrial genes encoding transfer ribonucleic acids [RNAs] for isoleucine and phenylalanine).</p><p class="headingAnchor" id="H4057326728"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The exact incidence and prevalence of BS and GS are unknown.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bartter Syndrome</strong> – The overall prevalence of all types of BS in North America and Western European countries is estimated between 1 per 40,000 to 50,000, based on data from the Framingham Heart Study that found a prevalence of 1:100,000 for BS types 1 and 2 due to <em>SLC12A1</em> and <em>KCNJ1</em> variants [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gitelman Syndrome</strong> – The reported prevalence for GS is estimated between 1 to 10:40,000, thus, GS probably is the most frequently inherited tubular disorder [<a href="#rid12">12,14</a>]. However, given the number of incidental diagnoses of asymptomatic individuals, the prevalence is likely higher.</p><p></p><p class="headingAnchor" id="H714088131"><span class="h1">CLINICAL FEATURES: BARTTER SYNDROME</span></p><p class="headingAnchor" id="H3600965041"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The term BS comprises a set of inherited salt-wasting disorders with impaired sodium chloride (NaCl) reabsorption in the thick ascending limb (TAL) of the loop of Henle that presents with hypokalemic metabolic alkalosis and normal or low blood pressure despite high renin and aldosterone levels  (<a class="graphic graphic_figure graphicRef131048" href="/d/graphic/131048.html" rel="external">figure 1</a>) (see <a class="local">'Bartter syndrome'</a> above). BS is characterized by typical gene-specific patterns, including the age of presentation based on the underlying genetic defect  (<a class="graphic graphic_table graphicRef132709" href="/d/graphic/132709.html" rel="external">table 2</a>) [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations", section on 'Pathophysiology'</a>.)</p><p class="headingAnchor" id="H2721309552"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>The following are typical symptoms seen in children with BS. The age of presentation and the presence/severity of symptoms vary depending on the underlying genetic defect  (<a class="graphic graphic_table graphicRef132709" href="/d/graphic/132709.html" rel="external">table 2</a>) [<a href="#rid15">15</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Polyhydramnios and premature delivery</p><p class="bulletIndent1"><span class="glyph">●</span>Polyuria, polydipsia</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical signs of hypovolemia</p><p class="bulletIndent1"><span class="glyph">●</span>Failure to thrive</p><p class="bulletIndent1"><span class="glyph">●</span>Poor growth</p><p></p><p>Symptoms based on the timing of presentation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antenatal presentation</strong> – Polyhydramnios is a common finding during pregnancy presenting between 22 and 25 weeks of gestation [<a href="#rid11">11</a>]. The onset and severity of polyhydramnios varies depending on the type of BS. In fetuses with pathogenic variants in <em>BSND</em> or <em>MAGED2</em> (BS types 4 and 5, respectively), polyhydramnios is usually observed earlier during pregnancy than BS type 1 (<em>SLC12A1</em>) and BS type 2 (<em>KCNJ1</em>). The severity of polyhydramnios is most severe for BS types 4 and 5, whereas, in BS type 3 (<em>CLCNKB</em>), polyhydramnios is either mild or absent.</p><p></p><p class="bulletIndent1">Although fetuses with BS type 5 have the most severe form of polyhydramnios, polyuria resolves spontaneously after birth within a few weeks and, at the latest, within the first two years of life [<a href="#rid10">10,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal presentation</strong> – All BS types except BS type 3 typically present in the neonatal period with preterm birth (median gestational age between 29 and 33 weeks) and massive polyuria (often exceeding 10 mL/kg/hour) starting at day 1 of life with rapid weight loss and evidence of hypovolemia. In contrast, individuals with BS type 3 are usually full term and do not exhibit signs of excessive urinary loss and hypovolemia during the neonatal period.</p><p></p><p class="bulletIndent1">Infants with BS type 4a and 4b also have sensorineural hearing loss and fail their newborn hearing screening test [<a href="#rid7">7,9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Older infants and young children</strong> – Individuals with BS type 3 typically present after one year of age with failure to thrive and polyuria/polydipsia [<a href="#rid16">16-18</a>]. Less frequent symptoms related to hypovolemia and salt loss include constipation, persistent thirst, salt craving, unexplained fever, hypotonia, and recurrent vomiting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Older children and adolescents</strong> – Although uncommon, BS can initially present in older children and adolescents primarily due to BS type 3. Symptoms may be similar to those seen in GS, including muscle weakness, fatigue, salt craving, thirst, nocturia, cramps, and constipation. In prepubertal children, there may be evidence of poor growth and pubertal delay. In rare cases, in this age group, BS can present with isolated nephrocalcinosis and high parathyroid hormone levels, mimicking primary hyperparathyroidism [<a href="#rid19">19</a>]. Of note, especially in BS type 1 and type 2, signs of a mild hyperparathyroidism may be detected in otherwise typical BS patients [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic patients</strong> – Incidental presentation in an asymptomatic individual is very uncommon but can occur when abnormal laboratory tests demonstrate hypokalemia metabolic alkalosis in a normotensive child, abdominal imaging demonstrates nephrocalcinosis, or after screening based on a positive family history [<a href="#rid16">16-18,21</a>].</p><p></p><p class="headingAnchor" id="H793099747"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Laboratory findings for BS include [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypochloremic metabolic alkalosis</strong> is a common finding in children with BS (see  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations", section on 'Mechanisms underlying associated clinical findings'</a>). However, neonates with BS type 2 often have transient acidosis and the degree of alkalosis is less pronounced in children with BS type 2 compared with those with other types of BS. In general, patients with BS type 3 tend to have the lowest plasma chloride levels (median 87, interquartile range 74 to 94 mEq/L [mmol/L]) followed by those with BS type 4 (median 94, interquartile range 84 to 100 mEq/L [mmol/L]) and the most pronounced alkalosis [<a href="#rid10">10,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypokalemia</strong> is a characteristic diagnostic feature with potassium levels that are less than 3 mEq/L (mmol/L) in most patients [<a href="#rid22">22</a>]. However, neonates with BS type 2 often have transient hyperkalemia after birth because loss of function <em>KCNJ1</em> variants initially result in impaired potassium secretion along the collecting duct [<a href="#rid22">22,23</a>]. Postnatally, hyperkalemia develops likely due to expression of alternative potassium channels that compensates for the dysfunction of KCNJ1.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated renin and aldosterone</strong> levels are due to the decreased NaCl entry into macula densa cells, which stimulates renin production [<a href="#rid24">24-26</a>]. Despite the activation of the renin-angiotensin system, patients with BS have low to normal blood pressure due to chronic hypovolemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low urine osmolality</strong> due to impaired concentrating ability is a key laboratory finding in BS. Patients typically have urine osmolality values equal and never greater than their plasma osmolality (isosthenuric urine) [<a href="#rid22">22</a>]. The concentrating defect is mainly due to impaired sodium transport along the TAL, leading to the loss of medullary interstitial hypertonicity and osmotic driving force for water reabsorption in the collecting duct that results in excessive amounts of dilute urine (polyuria) and volume depletion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urinary calcium</strong> varies based on the BS types and the underlying gene defect.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypercalcuria</strong> – Patients with BS type 1 and 2 have hypercalcuria  (<a class="graphic graphic_table graphicRef82389" href="/d/graphic/82389.html" rel="external">table 3</a>). For these infants, nephrocalcinosis is often detected after one or two months of life [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent2">Hypercalciuria may also be observed in neonates with BS type 5, but, due to the transient nature of the disease, it may disappear over time [<a href="#rid10">10,11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normocalciuria</strong> – Patients with BS types 3 and 4 usually have normocalciuria, although hypercalciuria has been described in some case reports. In addition, hypocalciuria has also been reported in patients with BS type 3 as seen with patients with GS. This phenotypic overlap is best explained by impaired NaCl reabsorption in the distal convolute tubule, in which the chloride channel ClC-Kb is also expressed. Studies of affected families with BS type 3 report that calcium excretion rates may differ among family members with the same mutation [<a href="#rid27">27,28</a>].</p><p></p><p>A more detailed discussion of the underlying mechanisms that result in these laboratory findings are found separately. (See  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations", section on 'Bartter-like phenotype'</a>.)</p><p class="headingAnchor" id="H453989717"><span class="h1">CLINICAL FEATURES: GITELMAN SYNDROME</span><span class="headingEndMark"> — </span>GS is an autosomal recessive disorder that usually presents with hypokalemia, metabolic alkalosis, hypomagnesemia, hypocalciuria, and normal or slightly low blood pressure with elevated renin and aldosterone levels [<a href="#rid12">12,29</a>].</p><p class="headingAnchor" id="H2643918904"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>GS presents mainly in adolescents and adults with the following signs and symptoms [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Muscle weakness and cramps, often after exercise, which may limit sport performance or endurance</p><p class="bulletIndent1"><span class="glyph">●</span>Fatigue</p><p class="bulletIndent1"><span class="glyph">●</span>Salt craving</p><p class="bulletIndent1"><span class="glyph">●</span>Thirst and polydipsia</p><p></p><p>Other less common presentations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Younger children ‒ Although uncommon, GS can present in younger children, including neonates [<a href="#rid22">22,29,30</a>]. In addition to the above findings, growth failure with short stature and pubertal delay may be observed in prepubertal children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Palpitations ‒ In some patients with GS, palpitations are also a presenting complaint, which is thought to be due to prolonged QT interval resulting from low serum potassium and magnesium levels [<a href="#rid12">12,31</a>]. (See <a class="local">'Complications'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic individuals ‒ GS can also be suspected after incidental laboratory testing detects hypokalemia metabolic alkalosis [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H2441173543"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>The following laboratory findings are characteristic of children with GS:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic hypokalemic (&lt;3.5 mEq/L) metabolic alkalosis</strong> with concomitant inappropriate urinary potassium wasting detected by a spot potassium-to-creatinine ratio &gt;13 mEq/g creatinine (&gt;1.5 mEq/mmol creatinine).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated renin and aldosterone levels</strong> – Reduction of extracellular fluid volume due to sodium chloride (NaCl) loss stimulates renin-angiotensin-aldosterone system. Despite the elevated renin and aldosterone levels, patients with GS have low to normal blood pressure due to chronic hypovolemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High urinary chloride excretion</strong> – Fractional excretion of chloride &gt;0.5 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypomagnesemia</strong> (&lt;1.70 mg/dL [0.7 mmol/L]) with inappropriate urinary magnesium wasting (fractional excretion of magnesium &gt;4 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypocalciuria</strong> – Low calcium:creatinine ratio &lt;0.05 mg/mg [0.15 mmol/mmol] [<a href="#rid15">15</a>].</p><p></p><p>A more detailed discussion of the underlying mechanisms that result in these laboratory findings is found separately. (See  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations", section on 'Gitelman-like phenotype'</a>.)</p><p class="headingAnchor" id="H2667121706"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of either BS or GS is clinically suspected uon recognition of their characteristic features but requires genetic testing for confirmation. Genetic testing will also differentiate among the various types of BS, although the different types of BS and GS can often be clinically distinguished  (<a class="graphic graphic_table graphicRef132709" href="/d/graphic/132709.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H104394343"><span class="h2">Antenatal diagnosis: Bartter syndrome</span><span class="headingEndMark"> — </span>Polyhydramnios detected at the beginning of the second trimester of gestation raises the clinical suspicion of BS [<a href="#rid3">3</a>]. There are two possible options to confirm the diagnosis: prenatal genetic testing and biochemical analysis of amniotic fluid. However, both measures are invasive and carry the risk of procedure-related complications, including fetal loss. As a result, we do not routinely perform these tests and we await postnatal genetic testing for confirmation of the diagnosis.</p><p>There may be clinical situations where the establishment of a confirmed diagnosis of BS is helpful for counseling of the couple and discussion of possible therapeutic measures. Whenever there is a need for prenatal diagnosis, genetic testing is the most reliable method. If genetic testing is unavailable or not informative, the biochemical measurement of the concentration of total protein and alpha-fetoprotein in the amniotic fluid can be used to calculate the Bartter index (total protein × alpha-fetoprotein), which has been reported to be useful in predicting the diagnosis of BS (sensitivity of 86 percent and specificity of 84 percent) [<a href="#rid32">32,33</a>]. In contrast, other biochemical components of the amniotic fluid such as electrolytes (high chloride) and/or aldosterone have not been shown to be useful in distinguishing BS from other causes of polyhydramnios [<a href="#rid33">33,34</a>].</p><p class="headingAnchor" id="H2964518873"><span class="h2">Postnatal diagnosis</span></p><p class="headingAnchor" id="H321085336"><span class="h3">When to suspect either Bartter or Gitelman syndrome</span><span class="headingEndMark"> — </span>The two inherited hypokalemic salt-wasting tubulopathies BS and GS are clinically suspected in individuals who present with hypokalemic hypochloremic metabolic alkalosis, high urinary chloride excretion, and normal to low blood pressure despite elevated renin and aldosterone levels. (See <a class="local">'Clinical features: Bartter syndrome'</a> above and <a class="local">'Clinical features: Gitelman syndrome'</a> above and  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations", section on 'Features common to hypokalemic salt-wasting tubulopathies'</a>.)</p><p>The following clinical features distinguish between the two disorders [<a href="#rid3">3,12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal presentation with evidence of hypovolemia due to massive polyuria is consistent with a clinical diagnosis of BS types 1, 2, 4a, and 4b but not GS or BS type 3. In particular, urinary concentrating ability is impaired in BS but fully preserved in GS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced urinary calcium excretion is observed in GS, whereas high or normal urinary calcium excretion is seen in most subtypes of BS. In particular, hypercalciuria occurs in patients with BS types 1 and 2, which may result in nephrocalcinosis by 1 or 2 months of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal magnesium wasting with hypomagnesemia is a prominent feature in GS but rarely occurs in BS, except patients with BS type 3 who also have a tendency towards low serum magnesium levels.</p><p></p><p class="headingAnchor" id="H1572383330"><span class="h3">Genetic testing</span><span class="headingEndMark"> — </span>The detection of pathogenic variants in one or more of the genes responsible for BS or GS confirms the clinical diagnosis  (<a class="graphic graphic_table graphicRef131049" href="/d/graphic/131049.html" rel="external">table 1</a>) [<a href="#rid3">3,12</a>]. For affected neonates, early genetic testing can differentiate among the different types of BS. This information would allow for avoidance of aggressive treatment for individuals with transient BS type 5, which typically resolves soon after birth, and identify infants with BS type 4a/b who also have sensorineural hearing loss in addition to renal salt-wasting.</p><p>Because of the number of causative genes, we suggest that next-generation sequencing (NGS) testing be performed using gene panels that should include at least <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600839&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoxvKHEeILathayIHXf3Piz&amp;TOPIC_ID=131435" target="_blank"><i>SLC12A1</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600359&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrHjld6cINu6QsBJdXiwAGn&amp;TOPIC_ID=131435" target="_blank"><i>KCNJ1</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606412&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoTdMGTrXMkw66hSZ%2FM2Vq9&amp;TOPIC_ID=131435" target="_blank"><i>BSND</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602024&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrEv0qgPPa19%2FubnQKwtt7H&amp;TOPIC_ID=131435" target="_blank"><i>CLCNKA</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602023&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqTD%2Fcsip0f9OWr9NgZTSD3&amp;TOPIC_ID=131435" target="_blank"><i>CLCNKB</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300470&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GY6BRfKcr1Pxyz%2BTzetl0q&amp;TOPIC_ID=131435" target="_blank"><i>MAGED2</i></a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600968&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqhcOVSWaUgDzdK8hjFTA8C&amp;TOPIC_ID=131435" target="_blank"><i>SLC12A3</i></a>. In children, the clinical sensitivity of NGS testing using this panel is approximately 75 percent and specificity is approximately 90 to 100 percent [<a href="#rid35">35</a>]. Of note, sensitivity decreases in adults due to the rise of secondary causes of hypokalemic metabolic alkalosis (eg, chronic use of diuretics and laxatives) [<a href="#rid36">36</a>]. Although large rearrangements (deletions or duplications) can be detected by NGS testing, a second independent method (eg, multiplex ligation-dependent probe amplification or quantitative polymerase chain reaction) should be used for confirmation. Large rearrangements are particularly frequent in the <em>CLCNKB</em> but have also been described in <em>KCNJ1</em>, <em>BSND</em>, and <em>MAGED2</em> [<a href="#rid7">7,11,37</a>].</p><p>In cases where the differential diagnosis is expanded, the gene panel can be extended to include genes responsible for congenital chloride diarrhea (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F126650&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RtC4p62hbR1YA0F%2BxVP0oO&amp;TOPIC_ID=131435" target="_blank"><i>SLC26A3</i></a>), HELIX syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F617579&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6%2F%2BXWmQLgHkVLyOuMnf3SQ&amp;TOPIC_ID=131435" target="_blank"><i>CLDN10</i></a>), EAST/SeSAME syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602208&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoMs2JCgoFI1e27V8d18rgu&amp;TOPIC_ID=131435" target="_blank"><i>KCNJ10</i></a>), hypokalemic tubulopathy and deafness (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F605722&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyormasok%2F0Dn68qz0uaRzhQ&amp;TOPIC_ID=131435" target="_blank"><i>KCNJ16</i></a>), kidney tubulopathy with cardiomyopathy (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608268&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaE6vyGmo4HKjN07rs03xDbH&amp;TOPIC_ID=131435" target="_blank"><i>RRAGD</i></a>), mitochondrial Gitelman-like syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F590045&amp;token=tEpDslnpc0F0kICl%2Fz7sFdjD%2BQo2qciDf1%2FZrD6VV4vxRT5ilZkVx9DBGbTiXmxp&amp;TOPIC_ID=131435" target="_blank"><i>MT</i>-<i>TI</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F590070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdjD%2BQo2qciDf1%2FZrD6VV4vrrzcGOrezlPjZ8wsREmBo&amp;TOPIC_ID=131435" target="_blank"><i>MT</i>-<i>TF</i></a>), autosomal dominant hypocalcemia (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601199&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqo1cuJ%2FFMrhGWYZmKTX3C3&amp;TOPIC_ID=131435" target="_blank"><i>CASR</i></a>), and type 1 pseudohypoaldosteronism (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600228&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrH%2FXAbzwdXWb8uPMeAGC%2BL&amp;TOPIC_ID=131435" target="_blank"><i>SCNN1A</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600760&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqCZno%2BGiZbWNei7abpjRGw&amp;TOPIC_ID=131435" target="_blank"><i>SCNN1B</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600761&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyppwEXoJkV8OV516Ul7nTTJ&amp;TOPIC_ID=131435" target="_blank"><i>SCNN1G</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600983&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrfnLv45epzuVfws%2BaI%2BnQB&amp;TOPIC_ID=131435" target="_blank"><i>NR3C2</i></a>). (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Genetic counselling should be offered to any patient with BS and to parents with an affected child and can help guide testing of other family members. Testing relatives is particularly useful to identify heterozygous female carriers in families with an index case carrying a <em>MAGED2</em> mutation [<a href="#rid10">10</a>].</p><p>Prenatal diagnosis and preimplantation genetic testing are feasible and may be considered on an individual basis with reliable genetic counselling, according to national ethical and legal standards.</p><p class="headingAnchor" id="H432786593"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of BS and GS depends on clinical manifestations, including age of presentation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antenatal</strong> – The differential diagnosis for BS types that present with polyhydramnios include (see  <a class="medical medical_review" href="/d/html/6781.html" rel="external">"Polyhydramnios: Etiology, diagnosis, and management in singleton gestations", section on 'Conditions associated with polyhydramnios'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Congenital chloride diarrhea due to fetal secretory diarrhea resulting in excessive amniotic fluid.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fetal conditions that result in decreased fetal swallowing, including esophageal and gastrointestinal obstruction, which can be primary (esophageal or duodenal atresia) or secondary (eg, diaphragmatic hernia), and neuromuscular disorders (eg, trisomy 18). These disorders can often be distinguished from BS by fetal ultrasound or abnormal karyotype.</p><p></p><p class="bulletIndent1">Although prenatal genetic testing and amniotic fluid biochemistry can be used to differentiate BS from other disorders associated with polyhydramnios, they are not recommended, due to significant adverse effects, including fetal loss. As a result, differentiating between BS and these conditions may need to be done after delivery. (See <a class="local">'Antenatal diagnosis: Bartter syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonates</strong> – The differential diagnosis for neonates with BS is based on the most common finding of significant hypovolemia associated with metabolic alkalosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pseudohypoaldosteronism type 1 is differentiated from BS as it is associated with hyperkalemia and metabolic acidosis, whereas BS typically is characterized by hypokalemic metabolic alkalosis. Important to note that patients with BS type 2 (<em>KCNJ1</em>) may mimic pseudohypoaldosteronism type 1 during the first weeks of life due to transient hyperkalemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Congenital chloride diarrhea, which also presents with hypokalemic metabolic alkalosis, can be differentiated from BS as it is associated with low urinary chloride excretion, whereas BS is characterized by high urinary chloride excretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Older infants and children</strong> – Beyond the neonatal period, the differential diagnosis for BS and GS can be challenging and depends on the presenting clinical finding.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nephrocalcinosis/urolithiasis</strong> is commonly observed in the following disorders as well as BS types 1 and 2.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Distal renal tubular acidosis is distinguished from BS by laboratory testing demonstrating metabolic acidosis rather than metabolic alkalosis.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Apparent mineralocorticoid excess is associated with hypokalemic hypochloremic alkalosis. However, apparent mineralocorticoid excess is characterized by hypervolemia and hypertension with low renin and aldosterone, findings that differentiate it from BS, which is characterized by hypovolemia, low/normal blood pressure, and high renin and aldosterone levels.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypovolemia associated with hypokalemic alkalosis</strong> is observed in patients with BS and GS as well as a subset of patients with cystic fibrosis (referred to as pseudo-BS) [<a href="#rid15">15</a>], surreptitious vomiting, and chronic use of laxatives [<a href="#rid3">3,12</a>]. A high chloride excretion rate distinguishes BS and GS from these other disorders, which are characterized by a low urinary chloride excretion [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent2">The differential diagnosis also includes chronic or surreptitious use of diuretics, which may have variable levels of urinary chloride excretion. However, this is unusual in children but, if present, it is difficult to be distinguished from GS and BS type 3.</p><p></p><p class="bulletIndent2">The following rare renal tubular disorders exhibit metabolic alkalosis and are differentiated from BS and GS by their characteristic clinical findings and confirmation by genetic testing [<a href="#rid3">3,12,38</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>EAST/SESAME syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F612780&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7SwUlg4PDioH6QPkfdcgGQ&amp;TOPIC_ID=131435" target="_blank">MIM #612780</a>; <em>KCNJ10</em>) [<a href="#rid39">39</a>]</p><p class="bulletIndent3"><span class="glyph">-</span>HNF1B nephropathy [<a href="#rid40">40</a>]</p><p class="bulletIndent3"><span class="glyph">-</span>HELIX syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F617671&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz72tifgArian3UCMeddN9KZ&amp;TOPIC_ID=131435" target="_blank">MIM #617671</a>; <em>CLDN10</em>) [<a href="#rid41">41,42</a>]</p><p class="bulletIndent3"><span class="glyph">-</span>Mitochondrial Gitelman-like syndrome (<em>MT</em>-<em>TI</em>, <em>MT</em>-<em>TF</em>) [<a href="#rid43">43</a>]</p><p class="bulletIndent3"><span class="glyph">-</span>Hypokalemic tubulopathy and deafness (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F619406&amp;token=tEpDslnpc0F0kICl%2Fz7sFbbHsBJVAXU52QtjSlxi7cUuwGIUK3nHbKjx%2B9F3a9kx&amp;TOPIC_ID=131435" target="_blank">MIM #619406</a>; <em>KCNJ16</em>) [<a href="#rid38">38</a>]</p><p class="bulletIndent3"><span class="glyph">-</span>Kidney tubulopathy with cardiomyopathy (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F620152&amp;token=tEpDslnpc0F0kICl%2Fz7sFZBX5WzE1SWgT2agv%2BTlJGx%2BESEwXZgQcegdRhd7XEHm&amp;TOPIC_ID=131435" target="_blank">MIM #620152</a>; <em>RRAGD</em>) [<a href="#rid44">44</a>]</p><p class="bulletIndent3"><span class="glyph">-</span>Autosomal dominant hypocalcemia (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601198&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypFVqjuE6oHTi6YNLYqynPK&amp;TOPIC_ID=131435" target="_blank">MIM #601198</a>; <em>CASR</em>) [<a href="#rid45">45</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypokalemia</strong> is a finding that occurs in a wide range of disorders, and the diagnostic evaluation to determine the underlying cause is discussed separately (see  <a class="medical medical_review" href="/d/html/97159.html" rel="external">"Hypokalemia in children", section on 'Evaluation to determine underlying etiology'</a>). BS and GS is typically differentiated from other causes of hypokalemia by their characteristic findings of persistent urinary potassium loss (urine potassium to creatinine ratio &gt;15 mg/g, creatinine [1.5 mEq/mmol], or fractional excretion rates &gt;15 percent), normal to low blood pressure, metabolic alkalosis, and high chloride excretion rate  (<a class="graphic graphic_algorithm graphicRef98041" href="/d/graphic/98041.html" rel="external">algorithm 1</a>).</p><p></p><p class="headingAnchor" id="H1176926585"><span class="h1">MANAGEMENT/THERAPY</span></p><p class="headingAnchor" id="H4188539040"><span class="h2">Prenatal therapy</span><span class="headingEndMark"> — </span>Although there are a few successful case reports of the use of serial amniocentesis and maternal administration of nonsteroidal antiinflammatory drugs (NSAIDs) to treat polyhydramnios due to BS, it remains uncertain whether this approach provides sufficient benefit to outweigh potential adverse effects, including fetal loss [<a href="#rid3">3</a>]. The management of severe polyhydramnios due to BS is provided by a multidisciplinary team and is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6781.html" rel="external">"Polyhydramnios: Etiology, diagnosis, and management in singleton gestations", section on 'Additional issues in patients with severe polyhydramnios'</a>.)</p><p class="headingAnchor" id="H873206326"><span class="h2">Postnatal therapy</span><span class="headingEndMark"> — </span>Postnatal therapy consists of initial repletion and maintenance therapy of fluid, sodium chloride (NaCl), and potassium. Because urinary losses are continuous for both NaCl and potassium, supplements should be administered in frequent doses throughout the day. For infants receiving continuous tube feeding, supplements can be added to the feed. In more severe cases, the use of NSAIDs may be needed.</p><p class="headingAnchor" id="H2587334647"><span class="h3">Sodium chloride</span><span class="headingEndMark"> — </span>Adequate daily NaCl consumption to account for tubular loss is one of the mainstays of managing BS and GS. (See  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations", section on 'Pathophysiology'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>BS – For most patients with BS, NaCl supplementation of at least 5 to 10 mEq/kg/day (mmol/kg/day) is needed to compensate for urinary losses.</p><p></p><p class="bulletIndent1">However, salt supplementation should be avoided in the uncommon setting of patients with BS types 1 and 2 who have secondary nephrogenic diabetes insipidus, who typically present with hypernatremia and hyposthenuric urine [<a href="#rid46">46</a>]. In these children with secondary nephrogenic diabetes insipidus, salt supplementation may lead to worsening polyuria and more severe hypernatremia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GS ‒ For GS, increased dietary salt consumption is usually sufficient to compensate for the tubular loss of salt.</p><p></p><p class="headingAnchor" id="H1583419125"><span class="h3">Potassium supplementation</span><span class="headingEndMark"> — </span>Hypokalemia is a characteristic finding for both BS and GS. In both disorders, symptoms due to hypokalemia are common and, in some cases, hypokalemia can lead to significant complications (eg, muscle weakness and paralysis, prolonged QT interval, and cardiac arrhythmias) [<a href="#rid3">3,12</a>]. However, the intake of large amounts of potassium is also associated with serious side effects including gastric ulcers, vomiting, and diarrhea. As a result, the goal of therapy is not to normalize potassium levels but to achieve a target of ≥3 mEq/L (mmol/L), which should alleviate symptoms associated with hypokalemia.</p><p>Potassium supplements should be given as <a class="drug drug_pediatric" data-topicid="13037" href="/d/drug information/13037.html" rel="external">potassium chloride</a> because chloride is the main anion lost in the urine [<a href="#rid3">3,12</a>]. <a class="drug drug_general" data-topicid="10225" href="/d/drug information/10225.html" rel="external">Potassium citrate</a> and <a class="drug drug_pediatric" data-topicid="13033" href="/d/drug information/13033.html" rel="external">potassium acetate</a> should be avoided as they could aggravate the alkalosis associated with these disorders. In our center, oral potassium chloride supplementation is administered at an initial dose of 1 to 2 mEq/kg/day (mmol/kg/day) in divided doses throughout the day administered in water, as a syrup, or as a slow-release formulation, based on patient preference. The dose is then modified with a target of maintaining a target potassium level ≥3 mEq/L (mmol/L). However, it has to be noted that this target level may not be reached in all patients. Potassium-rich foods are recommended; however, some of these foods contain high amounts of carbohydrates and calories. Similar to NaCl supplementation, potassium supplementation should be divided into as many doses as possible.</p><p class="headingAnchor" id="H1902717489"><span class="h3">Magnesium supplementation</span><span class="headingEndMark"> — </span>Hypomagnesemia (&lt;1.70 mg/dL [0.7 mmol/L]) is a common feature of GS as well as BS type 3 and may aggravate the complaints/complications associated with hypokalemia [<a href="#rid12">12</a>]. In affected individuals, oral magnesium supplementation may be needed to reach a targeted goal of 1.46 mg/dL (0.6 mmol/L).</p><p>For patients needing magnesium supplements, oral organic magnesium salts are recommended (eg, aspartate, citrate, lactate) because of their higher bioavailability as compared with <a class="drug drug_pediatric" data-topicid="12981" href="/d/drug information/12981.html" rel="external">magnesium oxide</a> or hydroxide [<a href="#rid47">47</a>]. Treatment of hypomagnesemia may also facilitate potassium supplementation because hypomagnesemia may worsen hypokalemia and render it refractory to potassium. Doses of magnesium need individual adjustment, but a reasonable starting daily dose of elemental magnesium in children is 5 mg/kg (0.2 mmol/kg) divided into three to four doses. A slow-release formulation is used whenever possible. Of note, gastrointestinal side effects are common (especially diarrhea), which often requires dose reduction.</p><p class="headingAnchor" id="H2877425623"><span class="h3">Nonsteroidal antiinflammatory drugs</span><span class="headingEndMark"> — </span>Treatment with NSAIDs for BS is based on the observation of increased production of prostaglandin E2, which contributes to high urinary NaCl losses [<a href="#rid48">48</a>]. Based on the available observational evidence demonstrating beneficial effects of NSAIDs, we suggest NSAIDs be given to symptomatic patients (eg, poor growth or recurrent bouts of hypovolemia) with BS who fail to adequately respond to salt supplementation and fluid therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice and administration of NSAIDs</strong> ‒ There are no data showing that one specific NSAID is more effective than another in the management of BS. Commonly used NSAIDs for BS include <a class="drug drug_pediatric" data-topicid="13380" href="/d/drug information/13380.html" rel="external">indomethacin</a> (daily dose of 1 to 3 mg/kg/day divided into two or four doses), <a class="drug drug_pediatric" data-topicid="13371" href="/d/drug information/13371.html" rel="external">ibuprofen</a> (daily dose 15 to 30 mg/kg divided into three doses), and the selective cyclooxygenase (COX)-2 inhibitor <a class="drug drug_pediatric" data-topicid="12999" href="/d/drug information/12999.html" rel="external">celecoxib</a> (daily dose 2 to 10 mg/kg divided into two doses).</p><p></p><p class="bulletIndent1">In our center, we use <a class="drug drug_pediatric" data-topicid="13380" href="/d/drug information/13380.html" rel="external">indomethacin</a> for infants and small children and <a class="drug drug_pediatric" data-topicid="12999" href="/d/drug information/12999.html" rel="external">celecoxib</a> in older children (&gt;5 years of age) and adolescents. For preterm and neonates, we begin with a low dose of 0.1 mg/kg/day indomethacin with a stepwise increase to 1.5 to 2 mg/kg/day according to changes in urinary output and aldosterone levels. For older infants and young children, higher doses may be needed (up to 3 mg/kg/day) to maintain euvolemia and adequate levels of electrolytes and fluid.</p><p></p><p class="bulletIndent1">Before starting NSAIDs, it is important to establish euvolemia with adequate replacement of salt and fluid losses because of the significant risk of acute renal failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> ‒ In our center, the main indications for NSAIDs are excessive polyuria that cannot be managed by replacement therapy alone, failure to thrive, growth retardation, and potentially dangerous electrolyte disturbances despite maximal supplementation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy data</strong> ‒ Supporting evidence for the use of NSAIDs to manage BS is based on observational studies and case series that report that NSAIDs decrease urinary prostaglandin E excretion [<a href="#rid49">49-52</a>], normalize renin and aldosterone levels [<a href="#rid49">49-53</a>], and result in the following clinical benefits:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreased NaCl and potassium supplementation due to a reduction in urinary excretion of NaCl and potassium [<a href="#rid49">49,52-55</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Decreased urine volume</p><p class="bulletIndent2"><span class="glyph">•</span>Decreased hypercalciuria [<a href="#rid56">56,57</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Improved weight gain and growth [<a href="#rid53">53,55,58-61</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects of NSAIDs</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal complications ‒ The use of nonselective COX inhibitors (<a class="drug drug_pediatric" data-topicid="13380" href="/d/drug information/13380.html" rel="external">indomethacin</a> or <a class="drug drug_pediatric" data-topicid="13371" href="/d/drug information/13371.html" rel="external">ibuprofen</a>) is associated with gastrointestinal complications including gastritis and gastric ulcer disease [<a href="#rid15">15,55</a>]. If a nonselective COX inhibitor is used, gastric acid inhibitors should be prescribed to reduce the risk of gastrointestinal complications [<a href="#rid3">3</a>]. The potential risk of serious gastrointestinal complications (eg, ulcers, perforation) due to NSAIDs, especially in preterm and term neonates, need to be weighed against the beneficial effects on renal salt loss in BS and avoiding the complications associated with significant hypovolemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic kidney disease (CKD) ‒ Individuals with BS appear to be at risk for CKD; however, it remains uncertain whether NSAIDs play a significant contributing role as there are additional risk factors for CKD, including prematurity and repeated bouts of hypovolemia [<a href="#rid3">3</a>]. (See <a class="local">'Complications'</a> below.)</p><p></p><p class="headingAnchor" id="H317540733"><span class="h3">Other management considerations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutritional support</strong> ‒ Poor weight gain and growth are common complications of BS. Nutritional support is focused on maximal caloric intake. In infants and small children, tube feeding may be helpful to provide optimal caloric intake as well as administration of salt and fluid supplements [<a href="#rid3">3</a>]. In older children and adolescents, foods rich in potassium and magnesium  (<a class="graphic graphic_table graphicRef143027 graphicRef143028" href="/d/graphic/143027.html" rel="external">table 4A-B</a>) should be encouraged as additional sources for electrolyte supply [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth hormone</strong> – Persistent growth failure despite adequate therapy of metabolic disturbances has been repeatedly reported in BS, especially in BS type 3 [<a href="#rid15">15,17,63</a>]. It remains unclear whether poor growth is due to acid/base or electrolyte disturbances in BS or whether it is an intrinsic part of the disorder. Although recombinant growth hormone has been used, poor response has been reported in patients with poor metabolic control [<a href="#rid15">15</a>]. Requirements before consideration of recombinant growth hormone therapy consist of an adequately maintained biochemical and fluid status and evaluation of the growth hormone axis in collaboration with a pediatric endocrinologist or other clinicians with expertise in poor growth. (See  <a class="medical medical_review" href="/d/html/5843.html" rel="external">"Treatment of growth hormone deficiency in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers</strong> have been considered in both BS and GS cases with persistent, symptomatic hypokalemia when supplements are not sufficient despite adherence or when side effects are unacceptable or both [<a href="#rid3">3,12</a>]. However, these agents may exacerbate renal salt wasting and increased polyuria resulting in critical hypovolemia, especially in patients with BS. As a result, we suggest that these drugs should not be used routinely and only be considered in individual cases for patients with severe symptoms due to hypokalemia despite maximization of routine treatment with NaCl and potassium supplementation, and NSAIDs for BS. These agents should only be prescribed by clinicians with expertise in caring for patients with BS.</p><p></p><p class="headingAnchor" id="H2426443723"><span class="h2">Follow-up care</span><span class="headingEndMark"> — </span>The follow-up care for patients with BS and GS is based on the age of the patient, severity of symptoms, and therapeutic interventions  (<a class="graphic graphic_table graphicRef132772" href="/d/graphic/132772.html" rel="external">table 5</a>). Care is provided by specialized centers with expertise in renal tubular disorders in conjunction with the individual's primary care provider.</p><p class="headingAnchor" id="H2233344684"><span class="h1">RESOURCES FOR PATIENTS</span><span class="headingEndMark"> — </span>It is imperative that individuals and family/caregivers are provided information regarding their underlying disease. This information can be accessed through a variety of means including patient led-forums and web-based resources. There is no evidence suggesting that participation in sports is deleterious, but children and their caregivers should be aware of the risk of volume depletion and receive education on preventive measures to avoid hypovolemia.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Frarediseases.org%2Frare-diseases%2Fbartters-syndrome%2F&amp;token=9E9IX7kiH9qRiTPgEvfhBXfzSfVr6Je40Jo5pwBzJ8UeqjttZHIW5FsMaTjg7gYiI2IVM1NeEESoKDcJJPpPTQ%3D%3D&amp;TOPIC_ID=131435" target="_blank">National Organization for Rare Disorders: BS</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Frarediseases.org%2Fgard-rare-disease%2Fgitelman-syndrome%2F&amp;token=9E9IX7kiH9qRiTPgEvfhBVi3KkiOY9rTNVr4YOX3yAlUOMFfA0pT5TGX4H9ifv8TSyWaIDjqEU5ZueqG87NknA%3D%3D&amp;TOPIC_ID=131435" target="_blank">National Organization for Rare Disorders: GS</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fukkidney.org%2Frare-renal%2Fpatient%2Fbartter-syndrome&amp;token=x2QgkzZslu%2FHcVtg5O59K6v33lcBYXyLqI9LVini9tGlxwJoJ1XyRIczXK5dEfVVp8lnbkBn3FAEYra3WCltpw%3D%3D&amp;TOPIC_ID=131435" target="_blank">UK Kidney Association: BS</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fukkidney.org%2Frare-renal%2Fpatient%2Fgitelman-and-type-3-bartter-syndromes&amp;token=vuETlrutr%2BP0xud4x92y70U9xX2dE%2BMoBBy6804vxMLU%2Bx8PHpzNaS2p7LahKzoidpWXBGwoNmlXA%2BoNZ6VDQH5zJ0sztiHiAtW6lbZ4ktE%3D&amp;TOPIC_ID=131435" target="_blank">UK Kidney Association: GS and type 3 BS</a></p><p></p><p class="headingAnchor" id="H3088248091"><span class="h1">COMPLICATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poor weight gain and growth impairment</strong> – These are common in patients with BS. As noted above, salt and electrolyte supplementation, use of nonsteroidal antiinflammatory drugs (NSAIDs), and optimal nutrition are used to improve weight gain and growth. Body weight and height should be measured at every pediatric follow-up visit. (See <a class="local">'Management/therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypokalemia</strong> – Complications due to hypokalemia may be life-threatening and include prolongation of the QT interval, which increases the risk of ventricular arrhythmias and sudden cardiac death [<a href="#rid3">3,12</a>]. For patients with persistent hypokalemia, an electrocardiogram is performed to assess QT interval and rhythm. Further cardiac workup is performed for patients with palpitations or syncope, which may include Holter monitoring and stress test. (See  <a class="medical medical_review" href="/d/html/97159.html" rel="external">"Hypokalemia in children", section on 'Cardiac findings'</a>.)</p><p></p><p class="bulletIndent1">The use of drugs that slow sinus rhythm or cause additional prolongation of the QT interval should be considered on an individual basis. These include negative chronotropic drugs (eg, beta blockers), or drugs that may induce or exacerbate hypomagnesemia (which aggravates hypokalemia) [<a href="#rid12">12</a>], such as proton pump inhibitors, macrolides, fluoroquinolones, <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a>, or antiviral drugs.</p><p></p><p class="bulletIndent1">For patients who require anesthesia, hypokalemia and hypomagnesemia can potentiate the effects of anesthetic agents [<a href="#rid3">3,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic kidney disease (CKD)</strong> – CKD (ie, proteinuria and decreased glomerular function) is reported in patients with BS, especially those with types 1, 4a, and 4b [<a href="#rid15">15,16,64,65</a>]. This is likely the result of multiple factors (preterm birth, repeated bouts of severe dehydration, chronic use of NSAIDs, nephrocalcinosis), and it is uncertain what role the underlying genetic defect plays in the development of CKD [<a href="#rid3">3,15</a>]. Some patients progress to kidney failure. In the few reported cases of kidney transplantation, all of the electrolyte and urinary concentrating abnormalities were corrected and there was no evidence of recurrent disease.</p><p></p><p class="headingAnchor" id="H1907109915"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> ‒ Bartter syndrome (BS) and Gitelman syndrome (GS) are inherited hypokalemic salt-losing tubulopathies with impaired salt (ie, sodium) reabsorption resulting in excretion of salt in excess of what is required for homeostasis  (<a class="graphic graphic_table graphicRef131049" href="/d/graphic/131049.html" rel="external">table 1</a>). (See <a class="local">'Terminology'</a> above and  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic classification and epidemiology</strong> ‒ (See <a class="local">'Genetic classification'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>BS</strong> is divided into several types based on the underlying gene defect that impacts presentation. The overall prevalence of all types of BS in North America and Western European countries is estimated between 1 per 40,000 to 50,000  (<a class="graphic graphic_table graphicRef132709" href="/d/graphic/132709.html" rel="external">table 2</a>). (See <a class="local">'Bartter syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>GS</strong> is caused by dysfunctional proteins that affect sodium chloride (NaCl) reabsorption in the distal convoluted tubule (DCT). Classic GS is due to biallelic pathogenic variants of the <em>SLC12A3</em> gene that encodes the NaCl cotransporter NCC expressed in the apical membrane of the DCT  (<a class="graphic graphic_figure graphicRef131045" href="/d/graphic/131045.html" rel="external">figure 2</a>). Other genes variants that have been identified in individuals with Gitelman-like syndromes. (See <a class="local">'Gitelman syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of BS</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Presentation</strong> – Presenting features of BS and the age of presentation vary depending on the underlying genetic defect. Manifestations include polyhydramnios, preterm delivery, polyuria, polydipsia, signs of hypovolemia, failure to thrive, and poor growth  (<a class="graphic graphic_table graphicRef132709" href="/d/graphic/132709.html" rel="external">table 2</a>). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory findings</strong> – Laboratory features include (see <a class="local">'Laboratory findings'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hypochloremic metabolic alkalosis</p><p class="bulletIndent3"><span class="glyph">-</span>Hypokalemia</p><p class="bulletIndent3"><span class="glyph">-</span>Elevated renin and aldosterone but with normal or low blood pressure</p><p class="bulletIndent3"><span class="glyph">-</span>Isosthenuric urine – Urine osmolality values equal but never greater than plasma osmolality</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of GS</strong> ‒ (See <a class="local">'Clinical features: Gitelman syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Presentation</strong> – GS presents mainly in adolescents and adults, with muscle weakness and cramps, fatigue, salt craving, thirst, and polydipsia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory findings</strong> – Laboratory features include hypokalemia, elevated renin and aldosterone with low to normal blood pressure, high urinary chloride excretion, hypocalciuria, and hypomagnesemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of either BS or GS is clinically suspected upon recognition of their characteristic features but requires genetic testing for confirmation. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of BS and GS depends on clinical manifestations, including age of presentation. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antenatal management</strong> – Serial amniocentesis and maternal administration of nonsteroidal antiinflammatory drugs (NSAIDs) are not used to routinely manage polyhydramnios due to BS, as the available evidence is insufficient to show that the benefit outweighs potential adverse effects, including fetal loss. The management of polyhydramnios is discussed separately. (See  <a class="medical medical_review" href="/d/html/6781.html" rel="external">"Polyhydramnios: Etiology, diagnosis, and management in singleton gestations", section on 'Additional issues in patients with severe polyhydramnios'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postnatal management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Repletion and maintenance of fluid, NaCl, and potassium</strong> ‒ (See <a class="local">'Postnatal therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with BS, NaCl supplementation of at least 5 to 10 mEq/kg/day (mmol/kg/day) and <a class="drug drug_pediatric" data-topicid="13037" href="/d/drug information/13037.html" rel="external">potassium chloride</a> supplementation at an initial dose of 1 to 2 mEq/day are required to compensate for urinary losses. Because urinary losses are continuous, supplements should be administered in frequent doses throughout the day.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with GS, increased dietary salt consumption is usually sufficient to compensate for the tubular loss of sodium. However, potassium supplementation may be needed to maintain target potassium level ≥3 mEq/L (mmol/L).</p><p></p><p class="bulletIndent2">If supplements are provided, they should be administered in frequent doses throughout the day as urinary losses are continuous. For patients with potassium supplementation, the target potassium goal is ≥3 mEq/L (mmol/L), which should alleviate symptoms associated with hypokalemia. (See <a class="local">'Postnatal therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NSAIDs</strong> – In more severe symptomatic cases of BS that fail to respond adequately to salt supplementation and fluid therapy, we suggest administrating NSAIDs in addition to routine supportive care (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Nonsteroidal antiinflammatory drugs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nutrition</strong> – Maximal caloric intake, which may include tube feeding, is required to reduce the risk of poor weight gain and poor growth that is commonly seen in patients with BS. (See <a class="local">'Other management considerations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Follow-up care</strong> – Care is provided by specialized centers with expertise in renal tubular disorders in conjunction with the individual's primary care provider. The frequency of follow-up visits depends on the age of the patient, severity of symptoms, and therapeutic interventions  (<a class="graphic graphic_table graphicRef132772" href="/d/graphic/132772.html" rel="external">table 5</a>). (See <a class="local">'Follow-up care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patient education</strong> – Education of patient and family/caregivers is provided by care providers, including access to information through patient led-forums and web-based resources. (See <a class="local">'Resources for patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> ‒ (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypokalemia</strong> – For both patients with BS and GS, complications due to <strong>hypokalemia</strong> may be life-threatening and include increased risk of ventricular arrhythmias and sudden cardiac death. Adequate <a class="drug drug_pediatric" data-topicid="13037" href="/d/drug information/13037.html" rel="external">potassium chloride</a> supplementation that increases potassium ≥3 mEq/L (mmol/L) reduces this risk.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Growth failure</strong> – Poor weight gain and growth impairment are common findings for children with BS who do not receive or respond adequately to medical therapy. Growth depends on optimizing medical therapy by providing adequate fluid and electrolyte supplementation and caloric intake and, in some cases, NSAIDs. For children who continue to have poor growth despite adequate medical therapy, growth hormone therapy may be considered. (See <a class="local">'Other management considerations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic kidney disease (CKD)</strong> – Proteinuria and decreased glomerular function have been observed in patients with BS especially those with types 1, 4a, and 4b. However, CKD is likely the result of multiple factors (preterm birth, repeated bouts of severe dehydration, chronic use of NSAIDs, nephrocalcinosis) and it is uncertain what role the underlying genetic defect plays in the development of CKD.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Downie ML, Lopez Garcia SC, Kleta R, Bockenhauer D. Inherited Tubulopathies of the Kidney: Insights from Genetics. Clin J Am Soc Nephrol 2021; 16:620.</a></li><li><a class="nounderline abstract_t">Blanchard A, Vallet M, Dubourg L, et al. Resistance to Insulin in Patients with Gitelman Syndrome and a Subtle Intermediate Phenotype in Heterozygous Carriers: A Cross-Sectional Study. J Am Soc Nephrol 2019; 30:1534.</a></li><li><a class="nounderline abstract_t">Konrad M, Nijenhuis T, Ariceta G, et al. Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders. Kidney Int 2021; 99:324.</a></li><li><a class="nounderline abstract_t">Simon DB, Karet FE, Hamdan JM, et al. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 1996; 13:183.</a></li><li><a class="nounderline abstract_t">Simon DB, Karet FE, Rodriguez-Soriano J, et al. Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet 1996; 14:152.</a></li><li><a class="nounderline abstract_t">Simon DB, Bindra RS, Mansfield TA, et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet 1997; 17:171.</a></li><li><a class="nounderline abstract_t">Birkenhäger R, Otto E, Schürmann MJ, et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 2001; 29:310.</a></li><li><a class="nounderline abstract_t">Estévez R, Boettger T, Stein V, et al. Barttin is a Cl- channel beta-subunit crucial for renal Cl- reabsorption and inner ear K+ secretion. Nature 2001; 414:558.</a></li><li><a class="nounderline abstract_t">Schlingmann KP, Konrad M, Jeck N, et al. Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med 2004; 350:1314.</a></li><li><a class="nounderline abstract_t">Laghmani K, Beck BB, Yang SS, et al. Polyhydramnios, Transient Antenatal Bartter's Syndrome, and MAGED2 Mutations. N Engl J Med 2016; 374:1853.</a></li><li><a class="nounderline abstract_t">Legrand A, Treard C, Roncelin I, et al. Prevalence of Novel MAGED2 Mutations in Antenatal Bartter Syndrome. Clin J Am Soc Nephrol 2018; 13:242.</a></li><li><a class="nounderline abstract_t">Blanchard A, Bockenhauer D, Bolignano D, et al. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2017; 91:24.</a></li><li><a class="nounderline abstract_t">Ji W, Foo JN, O'Roak BJ, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008; 40:592.</a></li><li><a class="nounderline abstract_t">Knoers NV, Levtchenko EN. Gitelman syndrome. Orphanet J Rare Dis 2008; 3:22.</a></li><li><a class="nounderline abstract_t">Walsh PR, Tse Y, Ashton E, et al. Clinical and diagnostic features of Bartter and Gitelman syndromes. Clin Kidney J 2018; 11:302.</a></li><li><a class="nounderline abstract_t">Seys E, Andrini O, Keck M, et al. Clinical and Genetic Spectrum of Bartter Syndrome Type 3. J Am Soc Nephrol 2017; 28:2540.</a></li><li><a class="nounderline abstract_t">Bettinelli A, Borsa N, Bellantuono R, et al. Patients with biallelic mutations in the chloride channel gene CLCNKB: long-term management and outcome. Am J Kidney Dis 2007; 49:91.</a></li><li><a class="nounderline abstract_t">Konrad M, Vollmer M, Lemmink HH, et al. Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. J Am Soc Nephrol 2000; 11:1449.</a></li><li><a class="nounderline abstract_t">Yıldız G, Torun Bayram M, Çinleti T, et al. Late onset Bartter syndrome: Bartter syndrome type 2 presenting with isolated nephrocalcinosis and high parathyroid hormone levels mimicking primary hyperparathyroidism. J Pediatr Endocrinol Metab 2022; 35:1298.</a></li><li><a class="nounderline abstract_t">Verploegen MFA, Vargas-Poussou R, Walsh SB, et al. Parathyroid hormone and phosphate homeostasis in patients with Bartter and Gitelman syndrome: an international cross-sectional study. Nephrol Dial Transplant 2022; 37:2474.</a></li><li><a class="nounderline abstract_t">Brochard K, Boyer O, Blanchard A, et al. Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. Nephrol Dial Transplant 2009; 24:1455.</a></li><li><a class="nounderline abstract_t">Peters M, Jeck N, Reinalter S, et al. Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med 2002; 112:183.</a></li><li><a class="nounderline abstract_t">Finer G, Shalev H, Birk OS, et al. Transient neonatal hyperkalemia in the antenatal (ROMK defective) Bartter syndrome. J Pediatr 2003; 142:318.</a></li><li><a class="nounderline abstract_t">Castrop H, Schießl IM. Physiology and pathophysiology of the renal Na-K-2Cl cotransporter (NKCC2). Am J Physiol Renal Physiol 2014; 307:F991.</a></li><li><a class="nounderline abstract_t">Oppermann M, Hansen PB, Castrop H, Schnermann J. Vasodilatation of afferent arterioles and paradoxical increase of renal vascular resistance by furosemide in mice. Am J Physiol Renal Physiol 2007; 293:F279.</a></li><li><a class="nounderline abstract_t">Oppermann M, Mizel D, Kim SM, et al. Renal function in mice with targeted disruption of the A isoform of the Na-K-2Cl co-transporter. J Am Soc Nephrol 2007; 18:440.</a></li><li><a class="nounderline abstract_t">Jeck N, Konrad M, Peters M, et al. Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype. Pediatr Res 2000; 48:754.</a></li><li><a class="nounderline abstract_t">Zelikovic I, Szargel R, Hawash A, et al. A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. Kidney Int 2003; 63:24.</a></li><li><a class="nounderline abstract_t">Bettinelli A, Bianchetti MG, Girardin E, et al. Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis: Bartter and Gitelman syndromes. J Pediatr 1992; 120:38.</a></li><li><a class="nounderline abstract_t">Tammaro F, Bettinelli A, Cattarelli D, et al. Early appearance of hypokalemia in Gitelman syndrome. Pediatr Nephrol 2010; 25:2179.</a></li><li><a class="nounderline abstract_t">Bettinelli A, Tosetto C, Colussi G, et al. Electrocardiogram with prolonged QT interval in Gitelman disease. Kidney Int 2002; 62:580.</a></li><li><a class="nounderline abstract_t">Allaf B, Dreux S, Schmitz T, et al. Amniotic fluid biochemistry in isolated polyhydramnios: a series of 464 cases. Prenat Diagn 2015; 35:1331.</a></li><li><a class="nounderline abstract_t">Garnier A, Dreux S, Vargas-Poussou R, et al. Bartter syndrome prenatal diagnosis based on amniotic fluid biochemical analysis. Pediatr Res 2010; 67:300.</a></li><li><a class="nounderline abstract_t">Rachid ML, Dreux S, Pean de Ponfilly G, et al. Prenatal diagnosis of Bartter syndrome: amniotic fluid aldosterone. Prenat Diagn 2016; 36:88.</a></li><li><a class="nounderline abstract_t">Ashton EJ, Legrand A, Benoit V, et al. Simultaneous sequencing of 37 genes identified causative mutations in the majority of children with renal tubulopathies. Kidney Int 2018; 93:961.</a></li><li><a class="nounderline abstract_t">Hureaux M, Ashton E, Dahan K, et al. High-throughput sequencing contributes to the diagnosis of tubulopathies and familial hypercalcemia hypocalciuria in adults. Kidney Int 2019; 96:1408.</a></li><li><a class="nounderline abstract_t">Feldmann D, Alessandri JL, Deschênes G. Large deletion of the 5' end of the ROMK1 gene causes antenatal Bartter syndrome. J Am Soc Nephrol 1998; 9:2357.</a></li><li><a class="nounderline abstract_t">Schlingmann KP, Renigunta A, Hoorn EJ, et al. Defects in KCNJ16 Cause a Novel Tubulopathy with Hypokalemia, Salt Wasting, Disturbed Acid-Base Homeostasis, and Sensorineural Deafness. J Am Soc Nephrol 2021; 32:1498.</a></li><li><a class="nounderline abstract_t">Bockenhauer D, Feather S, Stanescu HC, et al. Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. N Engl J Med 2009; 360:1960.</a></li><li><a class="nounderline abstract_t">Adalat S, Hayes WN, Bryant WA, et al. HNF1B Mutations Are Associated With a Gitelman-like Tubulopathy That Develops During Childhood. Kidney Int Rep 2019; 4:1304.</a></li><li><a class="nounderline abstract_t">Bongers EMHF, Shelton LM, Milatz S, et al. A Novel Hypokalemic-Alkalotic Salt-Losing Tubulopathy in Patients with CLDN10 Mutations. J Am Soc Nephrol 2017; 28:3118.</a></li><li><a class="nounderline abstract_t">Hadj-Rabia S, Brideau G, Al-Sarraj Y, et al. Multiplex epithelium dysfunction due to CLDN10 mutation: the HELIX syndrome. Genet Med 2018; 20:190.</a></li><li><a class="nounderline abstract_t">Viering D, Schlingmann KP, Hureaux M, et al. Gitelman-Like Syndrome Caused by Pathogenic Variants in mtDNA. J Am Soc Nephrol 2022; 33:305.</a></li><li><a class="nounderline abstract_t">Schlingmann KP, Jouret F, Shen K, et al. mTOR-Activating Mutations in RRAGD Are Causative for Kidney Tubulopathy and Cardiomyopathy. J Am Soc Nephrol 2021; 32:2885.</a></li><li><a class="nounderline abstract_t">Vargas-Poussou R, Huang C, Hulin P, et al. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol 2002; 13:2259.</a></li><li><a class="nounderline abstract_t">Bockenhauer D, van't Hoff W, Dattani M, et al. Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases. Nephron Physiol 2010; 116:p23.</a></li><li><a class="nounderline abstract_t">Ranade VV, Somberg JC. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther 2001; 8:345.</a></li><li><a class="nounderline abstract_t">Kömhoff M, Reinalter SC, Gröne HJ, Seyberth HW. Induction of microsomal prostaglandin E2 synthase in the macula densa in children with hypokalemic salt-losing tubulopathies. Pediatr Res 2004; 55:261.</a></li><li><a class="nounderline abstract_t">Reinalter SC, Jeck N, Brochhausen C, et al. Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 2002; 62:253.</a></li><li><a class="nounderline abstract_t">Nüsing RM, Reinalter SC, Peters M, et al. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide. Clin Pharmacol Ther 2001; 70:384.</a></li><li><a class="nounderline abstract_t">Vinci JM, Gill JR Jr, Bowden RE, et al. The kallikrein-kinin system in Bartter's syndrome and its response to prostaglandin synthetase inhibition. J Clin Invest 1978; 61:1671.</a></li><li><a class="nounderline abstract_t">Delaney VB, Oliver JF, Simms M, et al. Bartter's syndrome: physiological and pharmacological studies. Q J Med 1981; 50:213.</a></li><li><a class="nounderline abstract_t">Cunningham RJ, Brouhard BH, Berger M, et al. Long-term use of propranolol, ibuprofen, and spironolactone in the management of Bartter's syndrome. Pediatrics 1979; 63:754.</a></li><li><a class="nounderline abstract_t">Gasongo G, Greenbaum LA, Niel O, et al. Effect of nonsteroidal anti-inflammatory drugs in children with Bartter syndrome. Pediatr Nephrol 2019; 34:679.</a></li><li><a class="nounderline abstract_t">Vaisbich MH, Fujimura MD, Koch VH. Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol 2004; 19:858.</a></li><li><a class="nounderline abstract_t">Ohlsson A, Sieck U, Cumming W, et al. A variant of Bartter's syndrome. Bartter's syndrome associated with hydramnios, prematurity, hypercalciuria and nephrocalcinosis. Acta Paediatr Scand 1984; 73:868.</a></li><li><a class="nounderline abstract_t">Leonhardt A, Timmermanns G, Roth B, Seyberth HW. Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome. J Pediatr 1992; 120:546.</a></li><li><a class="nounderline abstract_t">Dillon MJ, Shah V, Mitchell MD. Bartter's syndrome: 10 cases in childhood. Results of long-term indomethacin therapy. Q J Med 1979; 48:429.</a></li><li><a class="nounderline abstract_t">Seidel C, Reinalter S, Seyberth HW, Schärer K. Pre-pubertal growth in the hyperprostaglandin E syndrome. Pediatr Nephrol 1995; 9:723.</a></li><li><a class="nounderline abstract_t">Puricelli E, Bettinelli A, Borsa N, et al. Long-term follow-up of patients with Bartter syndrome type I and II. Nephrol Dial Transplant 2010; 25:2976.</a></li><li><a class="nounderline abstract_t">Garin EH, Fennell RS 3rd, Iravani A, Richard GA. Treatment of Bartter's syndrome with indomethacin. Am J Dis Child 1980; 134:258.</a></li><li><a class="nounderline abstract_t">Francini F, Gobbi L, Ravarotto V, et al. The Dietary Approach to the Treatment of the Rare Genetic Tubulopathies Gitelman's and Bartter's Syndromes. Nutrients 2021; 13.</a></li><li><a class="nounderline abstract_t">Gil-Peña H, Mejia N, Alvarez-Garcia O, et al. Longitudinal growth in chronic hypokalemic disorders. Pediatr Nephrol 2010; 25:733.</a></li><li><a class="nounderline abstract_t">Jeck N, Reinalter SC, Henne T, et al. Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness. Pediatrics 2001; 108:E5.</a></li><li><a class="nounderline abstract_t">Palazzo V, Raglianti V, Landini S, et al. Clinical and Genetic Characterization of Patients with Bartter and Gitelman Syndrome. Int J Mol Sci 2022; 23.</a></li></ol></div><div id="topicVersionRevision">Topic 131435 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32238367" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Inherited Tubulopathies of the Kidney: Insights from Genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31285285" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Resistance to Insulin in Patients with Gitelman Syndrome and a Subtle Intermediate Phenotype in Heterozygous Carriers: A Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33509356" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8640224" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8841184" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326936" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11687798" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11734858" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Barttin is a Cl- channel beta-subunit crucial for renal Cl- reabsorption and inner ear K+ secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15044642" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Salt wasting and deafness resulting from mutations in two chloride channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27120771" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Polyhydramnios, Transient Antenatal Bartter's Syndrome, and MAGED2 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29146702" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence of Novel MAGED2 Mutations in Antenatal Bartter Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28003083" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18391953" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rare independent mutations in renal salt handling genes contribute to blood pressure variation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18667063" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Gitelman syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29942493" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical and diagnostic features of Bartter and Gitelman syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28381550" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical and Genetic Spectrum of Bartter Syndrome Type 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17185149" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Patients with biallelic mutations in the chloride channel gene CLCNKB: long-term management and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10906158" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35952717" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Late onset Bartter syndrome: Bartter syndrome type 2 presenting with isolated nephrocalcinosis and high parathyroid hormone levels mimicking primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35137195" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Parathyroid hormone and phosphate homeostasis in patients with Bartter and Gitelman syndrome: an international cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19096086" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11893344" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12640382" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Transient neonatal hyperkalemia in the antenatal (ROMK defective) Bartter syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25186299" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Physiology and pathophysiology of the renal Na-K-2Cl cotransporter (NKCC2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17494095" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Vasodilatation of afferent arterioles and paradoxical increase of renal vascular resistance by furosemide in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17215439" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Renal function in mice with targeted disruption of the A isoform of the Na-K-2Cl co-transporter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11102542" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472765" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1731022" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis: Bartter and Gitelman syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20552229" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Early appearance of hypokalemia in Gitelman syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12110021" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Electrocardiogram with prolonged QT interval in Gitelman disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26426702" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Amniotic fluid biochemistry in isolated polyhydramnios: a series of 464 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19915517" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bartter syndrome prenatal diagnosis based on amniotic fluid biochemical analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26528764" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prenatal diagnosis of Bartter syndrome: amniotic fluid aldosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29398133" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Simultaneous sequencing of 37 genes identified causative mutations in the majority of children with renal tubulopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672324" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : High-throughput sequencing contributes to the diagnosis of tubulopathies and familial hypercalcemia hypocalciuria in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9848791" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Large deletion of the 5' end of the ROMK1 gene causes antenatal Bartter syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33811157" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Defects in KCNJ16 Cause a Novel Tubulopathy with Hypokalemia, Salt Wasting, Disturbed Acid-Base Homeostasis, and Sensorineural Deafness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19420365" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31517149" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : HNF1B Mutations Are Associated With a Gitelman-like Tubulopathy That Develops During Childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28674042" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A Novel Hypokalemic-Alkalotic Salt-Losing Tubulopathy in Patients with CLDN10 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28771254" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Multiplex epithelium dysfunction due to CLDN10 mutation: the HELIX syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34607911" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Gitelman-Like Syndrome Caused by Pathogenic Variants in mtDNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34607910" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : mTOR-Activating Mutations in RRAGD Are Causative for Kidney Tubulopathy and Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12191970" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20733335" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11550076" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14630996" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Induction of microsomal prostaglandin E2 synthase in the macula densa in children with hypokalemic salt-losing tubulopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081585" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11673754" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/96139" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The kallikrein-kinin system in Bartter's syndrome and its response to prostaglandin synthetase inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6171004" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Bartter's syndrome: physiological and pharmacological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/440896" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long-term use of propranolol, ibuprofen, and spironolactone in the management of Bartter's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30426218" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effect of nonsteroidal anti-inflammatory drugs in children with Bartter syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15206026" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Bartter syndrome: benefits and side effects of long-term treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6395627" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A variant of Bartter's syndrome. Bartter's syndrome associated with hydramnios, prematurity, hypercalciuria and nephrocalcinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1340758" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/120550" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bartter's syndrome: 10 cases in childhood. Results of long-term indomethacin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8747113" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pre-pubertal growth in the hyperprostaglandin E syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20219833" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Long-term follow-up of patients with Bartter syndrome type I and II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6767392" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Treatment of Bartter's syndrome with indomethacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34578838" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The Dietary Approach to the Treatment of the Rare Genetic Tubulopathies Gitelman's and Bartter's Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19902272" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Longitudinal growth in chronic hypokalemic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11433084" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35628451" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical and Genetic Characterization of Patients with Bartter and Gitelman Syndrome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
